HK1148202A1 - Pharmaceutical solutions, process of preparation and therapeutic uses - Google Patents

Pharmaceutical solutions, process of preparation and therapeutic uses

Info

Publication number
HK1148202A1
HK1148202A1 HK11102314.2A HK11102314A HK1148202A1 HK 1148202 A1 HK1148202 A1 HK 1148202A1 HK 11102314 A HK11102314 A HK 11102314A HK 1148202 A1 HK1148202 A1 HK 1148202A1
Authority
HK
Hong Kong
Prior art keywords
preparation
therapeutic uses
pharmaceutical solutions
pharmaceutical
solutions
Prior art date
Application number
HK11102314.2A
Other languages
English (en)
Inventor
Eric Schenkel
Claire Poulain
Bertrand Dodelet
Domenico Fanara
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39643757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1148202(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of HK1148202A1 publication Critical patent/HK1148202A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
HK11102314.2A 2008-03-03 2011-03-08 Pharmaceutical solutions, process of preparation and therapeutic uses HK1148202A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08003915 2008-03-03
PCT/EP2009/052454 WO2009109547A1 (fr) 2008-03-03 2009-03-02 Solutions pharmaceutiques, procédé de préparation et utilisations thérapeutiques

Publications (1)

Publication Number Publication Date
HK1148202A1 true HK1148202A1 (en) 2011-09-02

Family

ID=39643757

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11102314.2A HK1148202A1 (en) 2008-03-03 2011-03-08 Pharmaceutical solutions, process of preparation and therapeutic uses

Country Status (21)

Country Link
US (1) US20110021786A1 (fr)
EP (1) EP2273975B8 (fr)
JP (6) JP2011513360A (fr)
KR (1) KR101353425B1 (fr)
CN (1) CN101945647B (fr)
AU (1) AU2009221177B2 (fr)
BR (1) BRPI0908421C1 (fr)
CA (1) CA2715685C (fr)
CY (1) CY1115254T1 (fr)
DK (1) DK2273975T3 (fr)
EA (1) EA018736B1 (fr)
ES (1) ES2474945T3 (fr)
HK (1) HK1148202A1 (fr)
HR (1) HRP20140634T1 (fr)
IL (1) IL207558A (fr)
MX (1) MX2010009222A (fr)
PL (1) PL2273975T3 (fr)
PT (1) PT2273975E (fr)
RS (1) RS53418B (fr)
SI (1) SI2273975T1 (fr)
WO (1) WO2009109547A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011513360A (ja) * 2008-03-03 2011-04-28 ユセベ ファルマ ソシエテ アノニム 医薬溶液、調製方法及び治療的使用
CN107243007A (zh) 2008-10-16 2017-10-13 约翰斯.霍普金斯大学 改善认知功能的方法和组合物
LT3372605T (lt) 2008-10-22 2022-02-10 Array Biopharma, Inc. Pakeistieji pirazolo[1,5-a]pirimidino junginiai, kaip trk kinazės inhibitoriai
WO2010057869A1 (fr) * 2008-11-18 2010-05-27 Ucb Pharma, S.A. Formules à libération prolongée comprenant un dérivé de 2-oxo-1-pyrrolidine
PL2790695T3 (pl) 2011-12-16 2016-07-29 Uni Pharma Kleon Tsetis Pharmaceutical Laboratories S A Kompozycja farmaceutyczna zawierająca (S)-2-(2-oksopirolidyn-1-ylo)butanamid
CN102525900A (zh) * 2012-01-19 2012-07-04 南京恒道医药科技有限公司 左乙拉西坦注射液及其制备方法
MX2014012461A (es) * 2012-04-19 2015-01-12 Bard Inc C R Soluciones intravenosas con estabilidad de ph mejorada bajo esterilizacion con oxido de etileno.
CA2891122C (fr) 2012-11-14 2021-07-20 The Johns Hopkins University Methodes et compositions pour le traitement de la schizophrenie
WO2014144663A1 (fr) 2013-03-15 2014-09-18 The Johns Hopkins University Procédés et compositions pour améliorer la fonction cognitive
EP2968220B1 (fr) 2013-03-15 2021-05-05 Agenebio, Inc. Procédés et compositions pour améliorer la fonction cognitive
CN103550143B (zh) * 2013-10-19 2019-05-14 浙江华海药业股份有限公司 一种左乙拉西坦注射液的制备方法
CN107810002B (zh) 2015-05-22 2021-01-05 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物
BR112018012870A2 (pt) 2015-12-30 2018-12-04 Adamas Pharmaceuticals Inc métodos e composições para o tratamento de transtornos relacionados à crise
AU2017246554B2 (en) * 2016-04-04 2022-08-18 Loxo Oncology, Inc. Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
HRP20230704T1 (hr) 2016-05-18 2023-10-27 Loxo Oncology, Inc. Priprava (s)-n-(5-((r)-2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida
CN106491523A (zh) * 2016-09-24 2017-03-15 北京万全德众医药生物技术有限公司 一种布瓦西坦口服溶液及其制备方法
EP3826610A4 (fr) * 2018-07-24 2022-05-04 Zenvision Pharma LLP Système d'administration de médicament par voie nasale de brivaracétam ou d'un sel de celui-ci
WO2020089826A1 (fr) * 2018-11-02 2020-05-07 Zenvision Pharma Llp Perfusion intraveineuse prête à l'emploi de brivaracétam ou d'un sel de celui-ci
EP3951452A4 (fr) 2019-03-28 2022-12-28 Toyobo Co., Ltd. Polariseur circulaire anti-réflexion et affichage d'image l'utilisant
CN113908120A (zh) * 2021-09-30 2022-01-11 北京诺康达医药科技股份有限公司 布立西坦药物溶液及其制备方法
CN114213306A (zh) * 2021-12-28 2022-03-22 海南鑫开源医药科技有限公司 一种布瓦西坦酸杂质的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
BRPI0511956A (pt) * 2004-06-11 2008-01-22 Ucb Sa processo para a preparação dos compostos, e, intermediários de sìntese
EP1731149A1 (fr) * 2005-06-08 2006-12-13 Ucb S.A. Utilisation de Brivaracetam pour le traitement de maladies caracterisées par l'épilepsie myoclonique progressive
JP2011513360A (ja) * 2008-03-03 2011-04-28 ユセベ ファルマ ソシエテ アノニム 医薬溶液、調製方法及び治療的使用
KR101286540B1 (ko) * 2008-04-16 2013-07-17 엘지디스플레이 주식회사 액정표시장치

Also Published As

Publication number Publication date
EA018736B1 (ru) 2013-10-30
JP2022169734A (ja) 2022-11-09
CA2715685A1 (fr) 2009-09-11
AU2009221177B2 (en) 2013-05-30
WO2009109547A1 (fr) 2009-09-11
EP2273975B8 (fr) 2014-12-17
JP2019089837A (ja) 2019-06-13
CN101945647A (zh) 2011-01-12
BRPI0908421C1 (pt) 2021-05-25
JP2020128384A (ja) 2020-08-27
ES2474945T3 (es) 2014-07-10
JP2015145382A (ja) 2015-08-13
BRPI0908421B8 (pt) 2020-08-18
CA2715685C (fr) 2015-04-28
HRP20140634T1 (hr) 2014-11-21
EP2273975A1 (fr) 2011-01-19
RS53418B (en) 2014-12-31
JP2017114890A (ja) 2017-06-29
PL2273975T3 (pl) 2014-09-30
PT2273975E (pt) 2014-07-17
AU2009221177A1 (en) 2009-09-11
US20110021786A1 (en) 2011-01-27
BRPI0908421B1 (pt) 2020-08-04
CN101945647B (zh) 2013-01-09
CY1115254T1 (el) 2017-01-04
KR20100126466A (ko) 2010-12-01
KR101353425B1 (ko) 2014-02-18
IL207558A0 (en) 2010-12-30
IL207558A (en) 2015-02-26
JP2011513360A (ja) 2011-04-28
SI2273975T1 (sl) 2014-09-30
DK2273975T3 (da) 2014-06-30
BRPI0908421A2 (pt) 2015-08-04
EA201001402A1 (ru) 2011-06-30
EP2273975B1 (fr) 2014-04-09
MX2010009222A (es) 2010-09-28

Similar Documents

Publication Publication Date Title
HK1148202A1 (en) Pharmaceutical solutions, process of preparation and therapeutic uses
MX2011002966A (es) Formas de dosificacion farmaceutica que comprenden poli (e-caprolactona).
PH12013502192A1 (en) Antibodies against human angiopoietin 2
HK1140940A1 (en) Titration of tapentadol
WO2010087947A3 (fr) Administration transdermique de diclofénac, de carbamazépine et de benzydamine
IN2012DN02805A (fr)
MX2011007930A (es) Conjugados de insulina cristalina.
MX2012001974A (es) Compuestos de biarilo y metodos de uso de los mismos.
SG171542A1 (en) Pharmaceutical composition comprising a strontium salt, vitamin d and a cyclodextrin
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
ZA200906853B (en) Aqueous hydrogen peroxide solution, process for its preparation and use thereof
TW200942524A (en) Novel aminomethyl benzene derivatives
TW200942530A (en) Pyridine compounds
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
UA107476C2 (uk) Фармацевтична субстанція на основі мітохондріально адресованих антиоксидантів
MX2011006721A (es) Formulacion farmaceutica de fenofibrato nanonizado.
MX2009008108A (es) Composicion farmaceutica que contiene una combinacion de tramadol y ketoprofeno.
IL211062A0 (en) Pharmaceutical uses of lanosta-8,24-dien-3-ols
UA96574C2 (ru) Использование ивабрадина для получения лекарств, предназначенных для лечения эндотелиальной дисфункции
UA89010C2 (ru) Комбинированное обезболивающее средство на основе кеторолака и дротаверина
WO2010139411A3 (fr) 17β-ALKYL-17α-OXY-ESTRATRIÈNES
UA92646C2 (ru) применение производных 2-оксоиндолин-3-глиоксиловой кислоты в качестве средств с актопротекторным действием
UA48243U (uk) Фармацевтична композиція
UA35660U (en) Use of antihomotoxic preparations as cytoprotectors
JO2775B1 (en) 3-indazolil 4-pyridyl isothiazole